Sign in Subscribe
Diseases

Ambroxol Hydrochloride Capsules Show Promise in Gaucher Disease Treatment

Strategic Insights

— 2 min read

Researchers at Amsterdam University Medical Center in the Netherlands have been investigating the use of ambroxol hydrochloride (AMB) as a potential treatment for neurological manifestations in Gaucher disease type 3 (GD3). Gaucher disease is a rare genetic disorder that affects the body's ability to break down certain lipids, leading to the accumulation of toxic substances in the body. The research focused on developing a high-dose AMB formulation that could be used in a clinical trial involving Dutch patients with GD3. The study aimed to create a suitable commercial AMB formulation, develop high-dose AMB capsules, and assess the quality of the formulated capsules. The researchers successfully developed and validated analytical methods, produced three validation batches, and observed rapid dissolution profiles. The optimized formulation of 75 mg AMB capsules met the specified criteria, indicating their potential use in clinical trials for GD3 treatment.

Key Takeaways:

  • Researchers at Amsterdam University Medical Center developed a high-dose ambroxol hydrochloride (AMB) formulation to treat neurological manifestations in Gaucher disease type 3 (GD3).
  • The study focused on creating a commercial AMB formulation and developing high-dose AMB capsules to be used in an n-of-1 clinical trial involving Dutch patients with GD3.
  • The researchers successfully developed and validated analytical methods, produced three validation batches, and observed rapid dissolution profiles.
  • The optimized formulation of 75 mg AMB capsules met the specified criteria, indicating their potential use in clinical trials for GD3 treatment.
  • The study demonstrated the efficacy of ambroxol hydrochloride in treating neurological manifestations in Gaucher disease type 3.
  • The researchers noted the importance of developing high-dose AMB capsules within the hospital pharmacy setting to ensure quality and uniformity.

Statistics:

  • 89.1% to 92.7% breakdown of ambroxol hydrochloride content in the initial batches
  • 12.4 to 17.6 Acceptance Values (AVs) of the initial ambroxol hydrochloride batches
  • 93.9% to 96.5% breakdown of ambroxol hydrochloride content in the optimized 75 mg validation batches
  • 12.4 to 14.9 Acceptance Values (AVs) of the optimized 75 mg validation batches
  • 80% dissolution rate of the ambroxol hydrochloride in 15 minutes

Sources:

  • Product Development of High-Dose Ambroxol HCl Capsules for an n-of-1 Clinical Trial Involving Dutch Patients with Gaucher Disease Type 3. Pharmaceutics, 2025, 17(4):417.
  • Amsterdam University Medical Center Researchers Release New Study Findings on Gaucher's Disease (Product Development of High-Dose Ambroxol HCl Capsules for an n-of-1 Clinical Trial Involving Dutch Patients with Gaucher Disease Type 3). Hematology Week. May 12, 2025; p 871.

Read more